Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Rheumatoid Arthritis

  Free Subscription


30.04.2018

1 Ann Med
1 BMJ
2 Clin Exp Rheumatol
1 Clin Rheumatol
1 Curr Opin Rheumatol
1 Drugs
1 PLoS One
2 Scand J Rheumatol
2 Z Rheumatol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Med

  1. AYRAVAINEN L, Heikkinen AM, Kuuliala A, Ahola K, et al
    Inflammatory biomarkers in saliva and serum of patients with rheumatoid arthritis with respect to periodontal status.
    Ann Med. 2018 Apr 23:1-38. doi: 10.1080/07853890.2018.1468922.
    PubMed     Text format     Abstract available


    BMJ

  2. ENGLAND BR, Thiele GM, Anderson DR, Mikuls TR, et al
    Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications.
    BMJ. 2018;361:k1036.
    PubMed     Text format     Abstract available


    Clin Exp Rheumatol

  3. PAPALOPOULOS I, Fanouriakis A, Kougkas N, Flouri I, et al
    Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study.
    Clin Exp Rheumatol. 2018;36:102-109.
    PubMed     Text format     Abstract available

  4. ZANKER M, Becher G, Arbach O, Maurer M, et al
    Improved adalimumab dose decision with comprehensive diagnostics data.
    Clin Exp Rheumatol. 2018;36:136-139.
    PubMed     Text format     Abstract available


    Clin Rheumatol

  5. PAPPAS DA, Nyberg F, Kremer JM, Lampl K, et al
    Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study.
    Clin Rheumatol. 2018 Apr 25. pii: 10.1007/s10067-018-4113.
    PubMed     Text format     Abstract available


    Curr Opin Rheumatol

  6. VAN DE SANDE MGH, van Vollenhoven RF
    Evolution of clinical trials for rheumatoid arthritis and spondyloarthritis.
    Curr Opin Rheumatol. 2018 Apr 24. doi: 10.1097/BOR.0000000000000516.
    PubMed     Text format     Abstract available


    Drugs

  7. AL-SALAMA ZT, Scott LJ
    Baricitinib: A Review in Rheumatoid Arthritis.
    Drugs. 2018 Apr 23. pii: 10.1007/s40265-018-0908.
    PubMed     Text format     Abstract available


    PLoS One

  8. OTSUKA Y, Kiyohara C, Kashiwado Y, Sawabe T, et al
    Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study.
    PLoS One. 2018;13:e0196368.
    PubMed     Text format     Abstract available


    Scand J Rheumatol

  9. SILJEHULT F, Arlestig L, Eriksson C, Rantapaa-Dahlqvist S, et al
    Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis.
    Scand J Rheumatol. 2018 Apr 27:1-6. doi: 10.1080/03009742.2018.1433232.
    PubMed     Text format     Abstract available

  10. TORRENTE-SEGARRA V, Bergstra SA, Salomon-Escoto K, Da Silva J, et al
    Is current smoking status and its relationship to anti-cyclic citrullinated peptide antibodies a predictor of worse response to biological therapies in rheumatoid arthritis patients?
    Scand J Rheumatol. 2018 Apr 23:1-4. doi: 10.1080/03009742.2017.1418423.
    PubMed     Text format     Abstract available


    Z Rheumatol

  11. HAUPL T, Skapenko A, Hoppe B, Skriner K, et al
    [Biomarkers and imaging for diagnosis and stratification of rheumatoid arthritis and spondylarthritis in the BMBF consortium ArthroMark].
    Z Rheumatol. 2018 Apr 24. pii: 10.1007/s00393-018-0458.
    PubMed     Text format     Abstract available

  12. KUIPERS JG, Koller M, Zeman F, Muller K, et al
    Adherence and health literacy as related to outcome of patients treated for rheumatoid arthritis : Analyses of a large-scale observational study.
    Z Rheumatol. 2018 Apr 24. pii: 10.1007/s00393-018-0449.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: